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ScienceDirectAdvances in elucidating the function of leucine-rich
repeat protein kinase-2 in normal cells and
Parkinson's disease
Matthew Taylor and Dario R. AlessiAbstract
Autosomal dominant missense mutations that hyperactivate
the leucine-rich repeat protein kinase-2 (LRRK2) are a
common cause of inherited Parkinson's disease and thera-
peutic efficacy of LRRK2 inhibitors is being tested in clinical
trials. In this review, we discuss the nuts and bolts of our cur-
rent understanding of how the LRRK2 is misregulated by
mutations and how pathway activity is affected by LRRK2
binding to membrane, microtubule filaments, and 14-3-3, as
well as by upstream components such as Rab29 and VPS35.
We discuss recent work that points toward a subset of Rab
proteins comprising key physiological substrates that bind new
sets of effectors, such as RILPL1/2, JIP3 and JIP4 after
phosphorylation by LRRK2. We explore what is known about
how LRRK2 regulates ciliogenesis, the endosomal– lysosomal
system, immune responses and interplay with alpha-synuclein
and tau and how this might be linked to Parkinson's’ disease.
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The clinical genetics of leucine-rich repeat protein
kinase-2 (LRRK2) can be traced back to 1978, when
researchers described a family in the Sagamihara City,Current Opinion in Cell Biology 2020, 63:102–113Japan, in which at least 5 generations were afflicted with
autosomal dominant inherited Parkinson’s disease (PD),
resembling idiopathic disease with age of onset typically
after 50 years [1]. Linkage analysis located the PD
causing mutation to a region within chromosome 12
termed PARK8 [2]. Contemporaneous work by two
groups in 2004 pinpointed the disease-causing muta-
tions to the gene encoding LRRK2 [3,4]. All members of
the Sagamihara family affected with PD exhibited a
heterozygous I2020T missense mutation within the
LRRK2 protein kinase domain [5]. It was soon realized
that LRRK2 mutations are the most frequent cause of
inherited PD, accounting for at least 5% of familial and
1e2% of idiopathic PD [6].
PDaffects anestimated7millionpeopleworldwide andall
attempts to slow the progression of Parkinson’s have thus
far failed [7]. The cardinal symptoms, shaking, rigidity,
and slowness of movement arise from degeneration of
dopaminergic neurons located within the substantia nigra
[8].Dementia andbehavioral disorders are also common in
the advanced stages of the disease [8].LRRK2 domain structure and impact of
pathogenic mutations
LRRK2 is a large multidomain enzyme bearing tandem
Roco type GTPase and catalytic kinase domains, in
addition to armadillo, ankyrin and leucine-rich repeats,
as well as a C-terminal WD40 domain (Figure 1).
LRRK2 exists predominantly as a dimer that likely
represents the active species [9e11]. It is expressed
most highly in immune cells (neutrophils, monocytes,
and B cells), lung, kidney, and intestine, with signifi-
cantly lower expression levels in brain [12C,13]. The
Roco domain comprises a Ras-like GTPase fold named
Roc (Ras of complex) followed by a dimerization fold
termed Cor (C-terminal of Roc). Roco domains are
found in diverse species including bacteria and plants
[14]. Mammals possess 4 proteins bearing a Roco
domain: 3 kinases (LRRK1, LRRK2, and DAPK) and a
scaffolding protein (MASL1). Roco GTPases bind GTP/
GDP with low micromolar affinity and may therefore not
necessitate a guanine nucleotide exchange factor (GEF)
or a GTPase activating proteins (GAP) enzyme towww.sciencedirect.com
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LRRK2 structure, upstream regulation and pathogenic mutations. Schematic of LRRK2 domain structure. ARM, Armadillo; ANK, Ankyrin; LRR,
Leucine-rich repeat; ROC, Ras of complex; COR, C-terminal of ROC; KIN, Kinase. Depicted are the clear-cut autophosphorylation site S1292 (Blue) and
other phosphorylation sites S910, S935, S955, S973 (Purple) with S910/S935 mediating 14-3-3 binding. Familial Parkinson’s disease pathogenic mu-
tations (Red) indicated with the proposed pathological mechanism enhancing kinase activity. Upstream regulation of LRRK2 shown previously, including
Rab29 recruitment to Golgi, possible LRRK2 recruitment by unknown Rabs (gray) to other organelle membranes or vesicles and the pathogenic VPS35
[D620N] mutation. Dashed Lines indicate more-than-one step processes. LRRK2, leucine-rich repeat protein kinase-2.
Regulation and function of LRRK2 Taylor and Alessi 103exchange nucleotides [15]. GTP binding is essential for
kinase activity as mutations that abolish GTP binding to
the ROC domain (T1348N) ablate LRRK2 kinase ac-
tivity [16,17C].
Seven well-characterized, pathogenic, and dominantly
inherited missense mutations are located within the Roc
(N1437H, R1441G/C/H), Cor (Y1699C), and kinase
(G2019S, I2020T) domains of LRRK2 [18] (Figure 1).
Substitution of serine for glycine at position 2019 in the
human LRRK2 protein (G2019S) is the most common
mutation. In addition, a LRRK2 variant located within
the WD40 domain (G2385R), that is relatively commonwww.sciencedirect.comin Chinese Taiwanese populations moderately increases
PD risk [19].
The pathogenic mutations within the LRRK2 kinase
domain (G2019S and I2020T) enhance LRRK2 activity
moderately, under 2-fold in vitro [20e22] and in vivo as
judged by phosphorylation of Rab substrates [23].
Autophosphorylation of LRRK2 at Ser1292 is enhanced
up to 4-fold by the G2019S mutation [24]. The G2019S
and I2020Tresidues lie within the DFGj (j= aliphatic
side chain I,L,V,M) motif found in all kinases that co-
ordinates a hydrophobic spine structure controlling
catalytic activity [25C]. In LRRK2, this motif possessesCurrent Opinion in Cell Biology 2020, 63:102–113
104 Cell Signallingthe sequence DYGI (residues 2017e2020). The
Tyr2018 residue within this motif is proposed to form a
hydrogen bond that serves as a ‘brake’ on kinase activity
by stabilizing LRRK2 in a less active conformation
[25C], a finding that has been confirmed in recent
structural work [26CC]. The G2019S and I2020T mu-
tations are thus thought to enhance LRRK2 catalytic
activity by disrupting the inhibited kinase domain
conformation [25C].
The LRRK2 Roc and Cor domain mutations (N1437H,
R1441G/C/H,Y1699C) suppress GTPase activity and
promote GTP binding [27]. Enhanced GTP binding is
thought to mediate the 3e4-fold increase in kinase
activity observed toward Rab substrates and auto-
phosphorylation at Ser1292 observed in vivo [23,24].
The G2385R mutation disrupts dimerization of the
WD40 domain, slightly enhancing LRRK2 activity
in vivo through an unknown mechanism [28C]
(Figure 1).
LRRK2 possesses multiple phosphorylated 14-3-3
binding residues, including Ser910 and Ser935 sites
[29]. Several PD-associated mutants (R1441 C/G,
Y1699C, I2020T) suppress Ser910 and Ser935 phos-
phorylation and hence reduced 14-3-3 binding. When
overexpressed, these mutants are recruited onto the
microtubule network [30] and LRRK2 association
occurs in a well-ordered, oligomeric periodic manner
[31]. Wild type LRRK2 or even the G2019S mutant
does not associate well with microtubules [25C]. How-
ever, inhibitors that bind to the ATP site, termed type I,
in a manner proposed to destabilize the inhibited kinase
conformation of LRRK2, promote recruitment of wild
type and G2019S LRRK2 to microfilaments [25C]. A
14 A˚ in situ cryo-electron tomography structure of the
LRRK2[I2020T] bound to microtubules indicates that
LRRK2 oligomerizes as a right-handed double-helix
around microtubules, which are left-handed [32CC].
The GTPase domain points toward the microtubule
polymer, suggesting that the GTPase cycle could regu-
late microtubule binding; the kinase domain is instead
exposed to the cytoplasm, perhaps poised to phosphor-
ylate substrates. The dimeric doughnut-shaped WD40
fold bridges two protomers together, with the G2385R
mutation abolishing microfilament association [32CC].
This structure reveals a second undefined oligomeriza-
tion interface mediated by non-catalytic domains
[32CC]. The in situ cryo-electron tomography structure
of the LRRK2[I2020T] differs significantly from a
model of full-length LRRK2 in solution, not bound to
microtubules, obtained using a combination of chemical
cross-linking, negative-stain EM, and small-angle X-ray
scattering [33].
Recent work has revealed a 3.5 A˚ cryo-EM structure of
the catalytic region of LRRK2 encompassing the ROC-Current Opinion in Cell Biology 2020, 63:102–113COR-kinase and WD40 domains, in which the LRRK2
kinase domain is in the inactive ‘open’ conformation
and Roc domain complexed to GDP [26CC]. Striking
features of the LRRK2 structure demonstrate major
interactions between the kinase domain and the
GTPase domain, suggesting how conformational
changes induced by GTP or GDP binding and hydro-
lysis might be coupled to kinase domain conformation
[26CC]. The extreme C-terminal 28 amino acids of
LRRK2 form an extended a-helix that binds along the
entire kinase domain, interacting with both its C- and
N-lobes. Interactors or possible phosphorylation sites
located within this C-terminal region could readily
impact on kinase activity [26CC]. Integrating data with
the 14 A˚ cryo-electron tomography in situ structure
[32CC] suggests that the LRR region wraps around the
N-lobe of the kinase domain, placing the known S1292
autophosphorylation site [24] in close proximity to the
kinase’s active site [26CC]. Further modeling and
experimental studies suggest that the LRRK2 kinase
domain needs to adopt the closed conformation to
interact with microtubules [26CC]. Type I inhibitors
that induce the closed kinase conformation, such as
MLi-2, promote microtubule binding and inhibit
kinesin and dynein motility in vitro by causing a
”’roadblock’” for motor proteins [26CC]. This is
reversed both in vitro and in vivo by adding type II in-
hibitors, such as GZD-824, that promote the open
conformation of the LRRK2 kinase domain [26CC]. In
future work, it would be interesting to investigate
whether microtubule-associated LRRK2 phosphory-
lates stalled motor proteins bound to cargo-associated
Rab GTPases and if so whether this leads to cargo
release. It will be also interesting to compare the
downstream biological effects of inhibitors that trap
LRRK2 in the microtubule binding closed conforma-
tion versus the nonbinding open conformation. As the
wild type, G2019S and G2385R mutants that do not
interact with microtubule filaments are still active and
phosphorylate Rabs in vivo, the role that microtubules
play in regulating LRRK2 and Rab phosphorylation
requires further analysis. Whether endogenous LRRK2
oligomerizes with microtubule filaments also needs to
be determined.
All LRRK2 type I inhibitors induce dephosphorylation
of Ser910 and Ser935 residues [34] and a cluster of other
close-by sites [35], which has been exploited to probe
in vivo efficacy of LRRK2 inhibitors. It is not understood
how LRRK2 activity or destabilization of the inactive
conformation of the LRRK2 kinase domain is linked to
Ser910/Ser935 phosphorylation and whether these sites
are regulated via a complex autophosphorylation mech-
anism or controlled through the activity of a protein
phosphatase-1 complex [17C,36]. How type II in-
hibitors impact LRRK2 phosphorylation has not been
tested.www.sciencedirect.com
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agents for PD
As pathogenic mutations increase kinase activity,
LRRK2 inhibitors might offer therapeutic benefit for
treating or preventing LRRK2-driven PD [37,38].
Elevated LRRK2 activity has also been observed in
idiopathic PD, suggesting that inhibitors may benefit
patients beyond those carrying LRRK2 mutations
[39CC]. Pharmaceutical companies have developed
LRRK2 inhibitors for treatment and prevention of PD
and clinical trials have commenced and/or are planned
(see https://clinicaltrials.gov). Studies with LRRK2-
deficient rodents [40] and nonhuman primates
treated with inhibitors have highlighted potential
concerns in lung (abnormal accumulation of lamellar
bodies in type 2 pneumocytes) and kidney (hyaline
droplets and a lipofuscin-like brown pigment in the
renal proximal tubular epithelium) [41]. These find-
ings generally phenocopy results obtained in LRRK2-
deficient mouse [42,43] and rat studies [40], indi-
cating that they are on target effects resulting from
ablation of LRRK2 kinase activity. These might result
from impacts that inhibition of LRRK2 play in regu-
lating endosomalelysosomal pathways (see in the
following context). However, recent studies using 3
structural diverse LRRK2 inhibitors at doses that
effectively suppress LRRK2 activity, suggest thatFigure 2
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www.sciencedirect.compathology is mild and reversible after inhibitor is
withdrawn [44CC]. Moreover, a further study has re-
ported that one in everyw500 humans is heterozygous
for a loss of function variant in LRRK2, resulting in a
w50% decrease in LRRK2 protein levels, but this
reduction in LRRK2 protein expression apparently has
no discernible effect on survival or health [45C].
Available data also suggest that carriers with reduced
levels of LRRK2 do not have impaired lung, liver or
kidney function [45C]. These results provide firm ev-
idence that therapy leading to a partial reduction of
LRRK2 kinase activity should be well tolerated.Rab proteins are key physiological LRRK2
substrates
The only validated physiological substrates for LRRK2
comprise a subset of Rab proteins including Rab8A and
Rab10 [23,46,47] (Figure 2). A number of other LRRK2
substrates have been proposed including endophilin A1
[48], ribosomal protein s15 [49], N-ethylmaleimide
sensitive fusion protein [50], synaptojanin [51], P62/
SQSTM1 [52] and auxillin [53], but to our knowledge
these findings have not been independently confirmed.
A number of Rabs orchestrate membrane trafficking,
including the processes of vesicle formation, vesicle
movement along actin and tubulin tracks, membraneRab
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ate Rabs (Rab1A/B, Rab3A/B/C/D, Rab5A/B/C, Rab8A/B, Rab10, Rab12,
esidue within the Switch-II motif. Rab membrane association is via C-
–GTP exchange and activation leading to a conformational change in the
. GTPase activating proteins (GAP) mediate Rab inactivation via GTP
ibitor (GDI) triggers membrane dissociation to the cytosol. GTP-bearing
diated Rab phosphorylation leads to dissociation of most Switch-II binding
rough an RH2-domain [46]. PPM1H mediates selective, LRRK2-substrate
gy domain 2.
Current Opinion in Cell Biology 2020, 63:102–113
106 Cell Signallingfusion and regulate synaptic vesicle trafficking [54].
Rabs switch between two conformations, an inactive
form bound to GDP and an active form bound to GTP,
interacting with effectors through an a-helical Switch-II
motif only in the GTP-bound state [55]. Rabs interact
with GDP dissociation inhibitors (GDIs), chaperone-
like molecules that solubilize and shuttle Rabs be-
tween membranes [56]. LRRK2 phosphorylates Rab
proteins at a conserved Thr/Ser motif lying at the center
of the Switch-II effector binding domain (Figure 2). All
the pathogenic LRRK2 mutants enhance Rab phos-
phorylation in vivo consistent with these comprising
relevant substrates in PD [23,46,47,57]. Phospho-
specific monoclonal antibodies [12C] and sensitive
mass spectrometry assays [58C] have been developed to
assess endogenous levels of LRRK2 phosphorylated
Rab10. In humans, phosphorylation of Rab10 has been
assessed in blood-derived neutrophils [59C] and
monocytes [60C].Figure 3
Boosting Immune System 
and Neuronal Inflammation
Vesicle Trafficki
LRR
Rabs
Lysosomal Stress
Defects in Autophagic
Pathways
LRRK2
Protection Against
Opportunistic Infections
Prolonged
Hyper-activation
Neuroinflammation
Parkinson
b)a)
Benefit at
young age
Inflammatory 
Conditions
(Crohn’s disease)
Proposed mechanisms linking LRRK2 with Parkinson's disease. (a). Pat
immune responses to infectious pathogens. Prolonged hyperactivation may le
chronic inflammatory conditions, such as Crohn’s disease. (b). LRRK2 is imp
other key regulators in the endolysosome system. Dysregulation may lead to
pathways and (2) impaired synaptic vesicle recycling in dopaminergic neurons
and in turn binding of RILPL1 in cholinergic interneurons of the dorsal striatu
hedgehog signals from dopaminergic neurons of the substantia nigra. This re
neurotrophic factor) signaling to dopaminergic circuits under stress conditions
interacting lysosomal-like protein 1; LRRK2, leucine-rich repeat protein kinas
Current Opinion in Cell Biology 2020, 63:102–113LRRK2 is 90% cytosolic and excluded from the nucleus
with 10% associating with multiple membrane and
vesicle structures [61CC]. The membrane associated
LRRK2 has greater specific activity than the cytosolic
LRRK2 [11]. LRRK2 associates with and dissociates
from distinct membrane compartments where it phos-
phorylates Rabs [61CC]. Phosphorylation of Rab pro-
teins does not affect GTPase activity but introduces
steric clashes preventing association with most Switch-
II motif binding effectors including GDI [23,46]
(Figure 2). As a result, phosphorylated Rabs become
trapped at that membrane location because they cannot
be retrieved by GDI [61CC]. A group of effectors that
include Rab interacting lysosomal-like protein 1
(RILPL1) and RILPL2 interact with LRRK2 phos-
phorylated Rab8 and Rab10 [46,62CC,63C]. An RILP
homology domain 2 (RH2) in RILPL1 and RILPL2
mediates interaction with phosphorylated Rab8A and
Rab10 [46]. The RH2-domain forms a central a-helicalInhibits
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hogenic mutations enhancing LRRK2-mediated activity result in boosted
ad to neuroinflammation, increasing PD susceptibility and is linked to
licated in vesicular trafficking pathways by phosphorylation of Rabs and
(1) lysosomal stress and subsequent defects in autophagic clearance
. (c) Elevated LRRK2-mediated activity increases phosphorylated Rab10
m. This leads to ciliogenesis defects and decreased response to Sonic
sults in the transmission of less neuroprotective GDNF (glial cell–derived
. Dashed lines indicate a more-than-one step process. RILPL1, Rab
e-2.
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pThr72 binding to a conserved arginine [64C]. RILPL1
and RILPL2 have been implicated in regulating cilio-
genesis [65]. PD mutations that activate LRRK2
interfere with ciliogenesis through a pathway involving
LRRK2 phosphorylated Rab8A and Rab10 binding
RILPL1 [62CC,63C]. In the brain of mice, LRRK2
pathogenic mutations disrupt ciliary signaling in a spe-
cific class of cholinergic interneurons of the dorsal
striatum, decreasing the ability of these neurons to
respond to a Sonic hedgehog signal received from
dopaminergic neurons that normally triggers these cells
to activate glial cell-derived neurotrophic factore
mediated neuroprotective signaling toward dopami-
nergic circuits [62CC] (Figure 3). JIP3 and JIP4 scaf-
folding proteins that have recently been shown to
interact with LRRK2 phosphorylated Rab10, also
possess an RH2-domain [64C] but the role these pro-
teins play are currently unknown.
At least 20 other Rab proteins are phosphorylated at the
equivalent Switch-II motif by kinases other than
LRRK2 [46], including Rab7A that is reportedly phos-
phorylated by LRRK1 promoting its interaction with
RILP that also possesses a RH2-domain [66C].
Recently, the PPM1H phosphatase has been shown to
dephosphorylate LRRK2 phosphorylated Rabs including
Rab8A and Rab10 in vivo [67CC]. PPM1H has high
catalytic activity and likely plays important roles with
other phosphatases to maintain Rab proteins in a
dephosphorylated state. It is localized to the Golgi and
cytosol and its knockdown suppresses primary cilia for-
mation, similar to pathogenic LRRK2 [67CC].Upstream regulators of LRRK2: Rab29 and
VPS35
A Golgi-resident Rab protein termed Rab29, encoded
within the PARK16 locus mutated in patients with PD
[68], has been genetically linked to LRRK2 and PD
[69,70]. In overexpression studies, Rab29 interacts with
the N-terminal domain of LRRK2 and recruits it to the
trans-Golgi network, and greatly stimulates its kinase
activity [17C,71C,72]. Pathogenic LRRK2 Roc and Cor
mutants that promote GTP binding are more readily
recruited to the Golgi and activated by Rab29 than wild
type LRRK2 [17C]. Rab29 has to be membrane- and
GTP-bound to recruit and activate LRRK2. Moreover,
LRRK2 phosphorylated Rab10 strikingly accumulates
on the membrane where LRRK2 is activated after
binding to Rab29, presumably due to phospho-Rab10’s
inability to bind GDIs [61CC]. LRRK2 also phosphor-
ylates Rab29 at two adjacent residues in the Switch-II
motif (Thr71 and Ser72) that may act as a negative
feedback loop releasing activated LRRK2 back into the
cytosol [17C]. Furthermore, variants within the LRRK2
and Rab29 genes synergistically increase Parkinson’s riskwww.sciencedirect.com[69], and studies in Caenorhabditis elegans indicated that
RAB29 (GLO-1) ortholog acts upstream of LRRK2
(LRK-1) in a pathway controlling axon termination [73].
A dominant inherited D620N mutation in the gene
encoding for VPS35, the cargo binding component of
the retromer complex, is associated with late onset PD
[74,75]. The retromer complex is made up of 3 pro-
teins (VPS35, VPS29, and VPS26) which package
specific endosomal cargoes into vesicles and tubules,
and deliver these to either the trans-Golgi network or
to the plasma membrane [76]. The VPS35[D620N]
mutation markedly elevates LRRK2-mediated phos-
phorylation of various Rab proteins in fibroblasts and
mouse tissues, as well as in human neutrophils and
monocytes [60C]. Further studies establish that
VPS35 plays a major role in controlling LRRK2 protein
kinase activity. Investigations undertaken in mouse
and Drosophila concluded that VPS35 and LRRK2
might operate in a common pathway regulating
endosomalelysosomal and Golgi sorting processes
[69]. Overexpression of VPS35 ameliorated pathogenic
effects on the eye, as well as locomotor deficits and
reduced lifespan observed in LRRK2 mutant flies
[77]. Drosophila VPS35 and LRRK2 control the same
set of synaptic vesicle processes, including dopami-
nergic synaptic release [78].Role of LRRK2 in endolysosomal stress and
synaptic vesicle trafficking
LRRK2 has been implicated in endolysosomal stress and
impacts on processes orchestrated by the lysosome, such
as autophagy and mitophagy [79]. Pathogenic mutations
lead to enlarged lysosomes with reduced acidification
and degradative capacity, an effect that is reversed by
LRRK2 inhibitors [80e82]. Although LRRK2 and Rabs
(Rab8a, Rab10, and Rab29) were reported to be targeted
to lysosomes [83] by interacting with the vacuolar-type
H þ -ATPase Pump a1 subunit to modulate lysosomal
pH [84], lysosomal localization of LRRK2 has not been
observed in other studies [61CC], and LRRK2 and most
Rabs have not been observed in proteomic analysis of
purified lysosomes [85]. A recent study reported that a
brain-penetrant LRRK2 kinase inhibitor improved
endolysosomal and autophagic defects as well as
neurodegeneration, caused by exposure of rats to the
rotenone toxin [86]. LRRK2 has also been reported to
influence synaptic vesicle recycling in dopaminergic and
other neurons in many studies [79]. Whether these ef-
fects are mediated through phosphorylation of Rabs or
other proposed substrates (endophilin A1 [48], N-
ethylmaleimideesensitive fusion protein [50], synap-
tojanin [51], auxillin [53]) require further analysis
(Figure 3). Involvement of Rabs in mediating the impact
of LRRK2 in endolysosomal stress and vesicle trafficking
could in the future be probed by manipulatingCurrent Opinion in Cell Biology 2020, 63:102–113
108 Cell Signallingexpression of the PPM1H phosphatase. Age-dependent
dopaminergic neurodegeneration and impairment of the
lysosomal pathway has been observed in double LRRK1
and LRRK2 knock-out mice but not in single knock-out
animals, suggesting that it would be important that
LRRK2 inhibitors being tested do not inhibit LRRK1
[87].
A common risk factor for PD is mutations in the gene
GBA1, that encodes for glucocerebrosidase-1, a lysosomal
hydrolase that catalyzes the hydrolysis of glucosylcer-
amide to glucose and ceramide [88]. Homozygous loss of
function mutations in GBA1 result in a lysosomal storage
disorder calledGaucher’s disease, but heterozygous loss of
function mutations represents a genetic risk factor for PD
[88]. A recent study has revealed that pathogenic LRRK2
mutations reduced lysosomal glucocerebrosidase activity
in a manner that is reversed by administration of LRRK2
kinase inhibitors in induced pluripotent stem celle
derived dopaminergic neurons [89C]. Mechanistic
studies suggest that LRRK2 mediates inhibition of
glucocerebrosidase activity via phosphorylation of Rab10
[89C]. These findings suggest that LRRK2 and GBA1
mutations may, in part, contribute to PD pathogenesis
through a common mechanism, potentially involving a
lysosomal stress pathway.LRRK2 in the immune system
LRRK2 is highly expressed in neutrophils, monocytes
and macrophages and there is increasing support for
LRRK2 playing a role in defense against intracellular
pathogens [90,91]. LRRK2 levels in monocytes and B
cells are elevated in patients with PD [92,93]. Variants
in the LRRK2 gene, such as N2081D located in the
kinase domain, enhance Rab10 phosphorylation and
have been linked to inflammatory conditions, including
Crohn’s disease [94CC]. The N2081 is located in the
kinase’s C-lobe and structural analysis places this in
close contact to the LRR region of LRRK2, suggesting a
functional relevance of the kinase domain-LRR inter-
face [26CC]. Other work has linked LRRK2 variants,
including the gain of function R1628P located in the Cor
domain, to be protective against leprosy [95]. Mice
lacking LRRK2 activity, or treated with an LRRK2 in-
hibitor, exhibit impaired ability to clear S. Typhimurium
infection, whereas G2019S knock-in mice are protected
[96,97C]. On the other hand, G2019S mutation aug-
ments immune cell chemotaxis and generates more
reactive oxygen species during virulent infection [97C].
LRRK2-dependent cellular pathways control Mycobacte-
rium tuberculosis replication by regulating phagosome
maturation [98C]. If the LRRK2 pathway is hyper-
activated over a long period, it could lead to neuro-
inflammation and increase susceptibility to PD.
Consistent with increased inflammation leading to PD, a
study reported a 28% increased risk of PD among pa-
tients with inflammatory bowel disease [99CC].Current Opinion in Cell Biology 2020, 63:102–113Moreover, with anti-inflammatory anti-TNF therapy, PD
risk was reduced by up to 78% [99CC]. LRRK2 trans-
genic mice display more severe colitis induced by
dextran sodium sulfate treatment than wild-type mice,
which was alleviated by treatment with LRRK2 in-
hibitors [100C]. The data suggests that in early life,
pathogenic mutations that activate LRRK2 could offer
protection against opportunistic infection. However,
stimulation of proinflammatory responses could increase
risk of developing neuroinflammation and PD, espe-
cially in later life (Figure 3).Potential crosstalk between LRRK2 and
alpha-synuclein and tau
A hallmark of sporadic PD is the presence of abnormal
protein aggregates termed Lewy bodies within the
cytoplasm of neurons, such as the substantia nigra which
are most impacted by disease. Alpha-synuclein is the
major component of Lewy bodies and consistent with
this being a driver of PD, mutations that increase the
expression or promote the aggregation of alpha-
synuclein are associated with familial forms of PD
[101]. Alpha-synuclein is expressed at high levels in the
brain and enriched in presynaptic nerve vesicles, but the
roles that it plays in regulating synaptic vesicle biology
are poorly understood. Alpha-synuclein can form higher
order fibril aggregate structures that can propagate
through adjacent neurons in the brain. This spread of
alpha-synuclein pathology to higher cortical regions
correlates with the progression of cognitive decline
observed in patients with PD [101]. There has been a
lot of interest in whether LRRK2 modulates alpha-
synuclein pathology. Several studies have reported that
LRRK2 overexpression or G2019S mutation accelerates
progression of alpha-synucleinemediated pathology and
aggregation in both primary neurons and mouse models
neuropathological changes, whereas deletion of LRRK2
alleviates these alterations [102-104C]. Moreover, the
G2019S mutation enhanced alpha-synuclein aggrega-
tion, whereas loss of LRRK2 decreased aggregation in
human-induced pluripotent stem cellederived neurons
[82,104C].
It has also been reported that antisense oligonucleotides
that lower LRRK2 expression in the brain reduced the
amount of pathological alpha-synuclein in the substantia
nigra of mice inoculated with pathological alpha-
synuclein [105]. However, another study aimed at
testing the benefit of a brain penetrable LRRK2 inhib-
itor on a well-characterized overexpression alpha-
synuclein mouse model, found that LRRK2 inhibition
did not reverse alpha-synuclein pathology, motor phe-
notypes or neuronal loss [106]. Although the vast ma-
jority of patients with sporadic PD display Lewy body
pathology autopsy, studies have unexpectedly revealed
that Lewy bodies are absent in a significant subset of
LRRK2 cases (20 of 37 LRRK2 cases studied and 6 of 17www.sciencedirect.com
Regulation and function of LRRK2 Taylor and Alessi 109G2019S PD cases) [107], suggesting that at least in
some cases, LRRK2 might drive PD independently from
alpha-synuclein or Lewy bodies.
Hyperphosphorylated tau protein accumulates in
neurofibrillary tangles in the brains of patients with
Alzheimer’s disease and, like alpha-synuclein, can be
transmitted between neurons. Hyperphosphorylated
tau aggregates are commonly observed in sporadic PD.
Recent work has shown that tau pathology is a promi-
nent feature of a large majority of LRRK2 mutation
carriers [108]. Overexpression [109] or knock-in muta-
tion [110] of pathogenic LRRK2 in mouse brain in-
creases Tau phosphorylation and in future work, it would
be interesting to explore whether LRRK2 inhibitors
impact Tau pathology and transmission.
The mechanistic link between LRRK2 and alpha-
synuclein or Tau is not known. Speculating, LRRK2
could impact aggregation and/or spreading of alpha-
synuclein or Tau through phosphorylation of Rab pro-
teins. This could influence endocytosis, autophagy and
lysosomal degradation of alpha-synuclein or Tau and
hence impact on their steady state levels. Indeed, a
recent study has provided evidence that LRRK2 kinase
regulates alpha-synuclein spreading in cell culture,
nematode, and rodent models via Rab35 phosphoryla-
tion [111C]. Recent work has also shown that VPS35
[D620N] knock-in mice manifest marked tau neuropa-
thology [112], and it would be interesting to also
investigate whether this is impacted with LRRK2
inhibitors.Concluding remarks
Researchers have made a reasonable start to deciphering
and interrogating the LRRK2 signaling network. High-
lights include the discovery that pathogenic mutations
activate LRRK2, identification of a subset of Rab pro-
teins as physiological LRRK2 substrates and devising
approaches to study pathway activity in vivo. The finding
that LRRK2 plays pivotal roles in modulating cilio-
genesis, the endolysosomal system and immune re-
sponses provides insights into how overactivation of
LRRK2 is linked to PD. The fact that several companies
are in the late stages of preclinical or early phase clinical
trials is really exciting. These efforts offer the strongest
hopes of developing the first treatments to slow pro-
gression or even halt LRRK2-driven PD, which if suc-
cessful would represent a major landmark in medicine. If
these therapies are well tolerated, they could be
considered as an approach to prevent PD onset in
humans carrying activating LRRK2 or other mutations,
such as in VPS35 and perhaps GBA1. Whether such
treatments will benefit a subset of patients with idio-
pathic PD and how to identify those who would respond
to LRRK2 inhibitor therapy are major questions that
need to be addressed.www.sciencedirect.comKey gaps remain in our knowledge of how LRRK2 is
regulated by upstream pathways, such as Rab29,
VPS35, the immune system, as well as environmental
factors including toxins, herbicides and pesticides, or
other PD genes and risk variants. Structural insights
into how LRRK2 is regulated and activated, and roles
that membrane association, as well as the GTPase
domain, microtubule filament and 14-3-3 binding play
need to be better defined. Individual functions of the
different Rab proteins that are phosphorylated by
LRRK2 and the effectors that interact with these after
they are phosphorylated need to be determined, as well
as how this ultimately impacts downstream biology. It
will be important to comprehend what are the most
relevant Rab substrates that link LRRK2 to PD using
endogenous systems. Our understanding of how
LRRK2 regulates the endo-lysosomes is still poorly
described and future work should focus on gaining
mechanistic insights into this important pathway that is
likely key to understanding how LRRK2 is linked to
PD.
It should be noted that although the LRRK2 mutant
mouse and rat knock-in models have been useful to
study the immediate biology that LRRK2 regulates,
such as Rab phosphorylation and closely linked down-
stream biology, these animals do not recapitulate PD.
Understanding the reasons for this and developing a
faithful mammalian model that develops LRRK2-driven
PD would greatly benefit our understanding of how
LRRK2 biology is linked to PD.Author contributions
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